The global bispecific antibodies market size was valued at USD 12.47 billion in 2024 and is projected to reach around USD 484.88 billion by 2034, Marking a substantial CAGR of 44.2% over the forecast period 2024 to 2034.
The Complete Study is Immediately Accessible | Download the Sample Pages of this Report@ https://www.precedenceresearch.com/sample/3977
Bispecific Antibodies Market: An Overview and Industry Potential
The bispecific antibodies market continues to grow due to the use of BsAbs in diagnostics. In general, bsAb is designed to bind a specific antigen and a detection moiety (e.g., horseradish peroxidase). Therefore, the bsAb can act as a cross-linker that binds both the antigen and the reporter molecules.
The success of bispecific antibodies has attracted the interest of pharmaceutical companies, and different companies have developed new models. Recent studies have reported the effectiveness of a new bispecific antibody, BiS4αPa, in treating P. aeruginosa. Bispecific antibodies are designed to bind simultaneously to two different epitopes or antigens. This dual effect enables bispecific antibiotics to bind to two antigens on the same cell, increasing target specificity.
· For Instance: In August 2024, Merck agreed to terms to acquire CN201, a novel bispecific antibody being developed by Curon Biopharmaceutical to treat B-cell diseases. According to Merck, the distributor will acquire all rights, and Curon will receive an upfront payment of $700 million.
For questions or customization requests, please reach out to us @ sales@precedenceresearch.com | +1 804 441 9344
Bispecific Antibodies Market Highlights:
· North America dominated the market with the largest market share of 88% in 2023.
· Europe is projected to grow at a double digit CAGR of 46.5% between 2024 and 2034.
· By indication, the cancer segment accounted for the biggest market share in of 68% 2023.
· By indication, the inflammatory and autoimmune disorders segment is anticipated to witness rapid growth at a significant CAGR during the projected period.
· By distribution channel, the hospital pharmacies segment contributed the highest market share of 43.5% in 2023.
· By distribution channel, the retail pharmacies segment is anticipated to grow at a significant CAGR of 37.5% over the projected period.
Major Trends in Bispecific Antibodies Market:
· Cancer Treatment: Bispecific antibodies (bsAb) provide new cancer treatments by targeting different antigens through different mechanisms of action, leading to the growth of the bispecific antibodies market.
· Drug Delivery: The ability of bispecific antibodies to target two targets broadens their applications to a variety of therapies, improving treatment and patient outcomes, and leading to the growth of the bispecific antibody market.
· Diseases Diagnosis: Immunoassays based on bispecific antibodies have been used in patients with infectious diseases such as tuberculosis, hepatitis B, E. coli, Bordetella pertussis, and SARS, leading to the growth of the bispecific antibodies market.
Discover Additional Market Size and Growth with Our Related Reports:
Antibodies in Monoclonal Antibodies Market Size and Growth 2023 to 2033:
The global monoclonal antibodies market size was evaluated at USD 226.63 billion in 2023 and is projected to surpass around USD 729.43 billion by 2033, at a CAGR of 12.4%.
Driven by increasing investments by the top pharmaceutical companies in genomic research and development by leading pharmaceutical companies and the emergence of new technologies such as next-generation sequencing (NGS), the market is observed to expand rapidly. Monoclonal antibodies are widely accepted biological products and are expected to offer major growth opportunities to marketers in the future.
Antibodies in Polyclonal Antibodies Market Size and Growth 2023 to 2034:
The global polyclonal antibodies market size is expected to be valued at USD 1.61 billion in 2024 and is anticipated to reach around USD 2.81 billion by 2034, expanding at a CAGR of 5.73% over the forecast period from 2024 to 2034 as the demand should be driven from by cancer, infectious diseases and antibody research, as well as demand from emerging economies such as the US, China, and others.
Research Antibodies Size and Growth 2023 to 2034:
The global research antibodies market size is calculated at USD 4.41 billion in 2024 and is projected to surpass around USD 7.22 billion by 2034, growing at a CAGR of 5.05% from 2024 to 2034. The market is expanding due to the increase in research academies and industry collaborations, increasing R&D investments, and increasing proteomics research, which is an important part of biotechnology and pharmaceutical research.
Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/3977
Bispecific Antibodies Market Report Coverage
|
Report Attribute |
Key Statistics |
|
Market Size in 2024 |
USD 12.47 Billion |
|
Market Size in 2025 |
USD 17.99 Billion |
|
Growth Rate from 2024 to 2034 |
44.2% |
|
U.S. Market Size in 2023 |
USD 5.34 Billion |
|
U.S. Market Size by 2034 |
USD 305.67 Billion |
|
Leading Region |
North America |
|
Fastest Growing Region |
46.5% |
|
Base Year |
2023 |
|
Forecast Period |
2024 to 2034 |
|
Segments Covered |
By Indication and By Distribution Channel and By Region |
|
Regions Covered |
North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Bispecific Antibodies Market Regional Outlook U.S. Bispecific Antibodies Market Size
and Forecast 2024 to 2034 The U.S. bispecific antibodies market size is
calculated at USD 7.71 billion in 2024 and is expected to hit around USD 305.67
billion by 2034, growing at a CAGR of 44.5% from 2024 to 2034. North America’s Sustained Dominance in Bispecific
Antibodies Market North America has emerged as a major region
in the bispecific antibodies market, with the largest share of advanced
biotechnology and biomanufacturing to develop innovative solutions in the areas
of health, climate change, energy, food security, agriculture, supply chain
resilience, and national and commercial security. Biotechnology is using the
power of biology to create new services and products, provide growth
opportunities in the US economy and employment, and improve the quality of life
and the environment. The top biotech companies in the region
represent a wide range of expertise from genomics to
pharmaceuticals, clinical trials,
therapeutics, clinical data, and more, which is driving the growth of the
bispecific antibodies market. ·
In April 2023, The U.S. government announced
that it is improving and enhancing the compilation of government designed to
"advance biotechnology and biomanufacturing innovations to achieve a
sustainable, safe, and secure U.S. bioeconomy" and to identify and
evaluate the economic benefits of the U.S. bioeconomy. Advancements in Biotech and Research
Institutions: Europe to Experience a Major Growth Europe region is expected to grow at a
notable rate during the forecast period as the new biotech consumer is focused
on several trends such as pharmaceuticals & process services, medical &
personal care, contract research organization (CRO), and
contract management organization (CMO). Europe is home to world-class research
institutions, medical centers, and hospitals that provide a solid foundation
for the discovery and development of new research and treatments. Europe’s
strength as a global force in research and advertising has yet to translate
into new patented drugs, which is driving the growth of the bispecific
antibodies market. ·
In October 2023, EpimAb Biotherapeutics, a
clinical-stage biopharmaceutical company specializing in the development of multispecific
antibodies, and Almirall, a global biopharmaceutical company focused on
dermatology, announced a license agreement on the development of
bispecific antibodies for up to three undisclosed target pairs. Bispecific Antibodies Market
Segmentation: By Indication,
the cancer segment held the highest market share as
recent advances in cancer treatment using bispecific antibodies have
revolutionized the treatment strategies for cellular malignancies, encouraging
the exploration of different
types of vaccines. By distribution
channel, the hospital pharmacies segment has
held the largest market share as hospital pharmacies have specialized skills
and knowledge that can support the development of prescription drugs and play a
key role in the reporting process such as providing appropriate feedback to
practitioners. Bispecific Antibodies Market Top Compan ·
Adimab, Innovent Biologics, Inc (U.S.) ·
Affimed GmbH (China) ·
Amgen Inc (Germany) ·
AstraZeneca (U.K.) ·
Xencor (U.S.) ·
Sanofi (France) ·
F. Hoffmann-La Roche Ltd (Switzerland) ·
Regeneron Pharmaceuticals Inc (U.S.) ·
Eli Lilly (U.S.) ·
Pieris Pharmaceuticals, Inc (U.S.) ·
Mereo BioPharma Group plc (U.K) ·
Sobi, TG Therapeutics Inc (Swden) ·
Merus (Netherlands) ·
MacroGenics, Inc (U.S.) ·
Genmab A/S (Denmark) ·
Emergent BioSolutions Inc (U.S.) ·
Alteogen (South Korea) ·
Astellas Pharma Inc (Japan) ·
Novartis AG (Switzerland) ·
CELGENE CORPORATION (U.S.) What is Going Around the Globe? ·
In September 2024, Canopy, the first oncology Continuous Care Platform for oncology,
announced platform-wide support for bispecific antibodies. This support
includes teletherapy care for CRS and ICAN, intelligent triage algorithms, and
decision support methods. ·
In February 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA)
has granted the company a critical review biologics License Application (BLA)
for elranatamab, an investigational B cell maturation antigen (BCMA)
CD3-targeting bispecific antibody (BsAb) for the treatment of patients with
relapsed or refractory multiple myeloma (RRMM). The research report categorizes the bispecific
antibodies market into the following segments and subsegments: By Indication By Distribution Channel By Geography Immediate Delivery Available | Buy This
Premium Research Report@ https://www.precedenceresearch.com/checkout/3977 You can place an
order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 804 441 9344 About Us Precedence Research is a worldwide market
research and consulting organization. We give an unmatched nature of offering
to our customers present all around the globe across industry verticals.
Precedence Research has expertise in giving deep-dive market insight along with
market intelligence to our customers spread crosswise over various
undertakings. We are obliged to serve our different client base present over
the enterprises of medicinal services, healthcare, innovation, next-gen
technologies, semi-conductors, chemicals, automotive, and aerospace &
defense, among different ventures present globally. Web: https://www.precedenceresearch.com Our Blogs: https://www.towardshealthcare.com https://www.towardspackaging.com https://www.towardsevsolutions.com For Latest Update Follow Us: Thanks for reading you can also get
individual chapter-wise sections or region-wise report versions such as North
America, Europe, or Asia Pacific. Browse More Press Releases: ·
DNA Forensics Market Size
to Surpass USD 5.52 billion by 2033 ·
Cosmetovigilance Market
Size Expected to Reach USD 17.60 Bn by 2033 ·
Acute Lymphocytic
Leukemia Therapeutics Market Size to Surpass USD 9.17 Bn by 2033 ·
Influenza Vaccine Market
Size to Surpass USD 18.02 Billion by 2034 ·
Inhalable Drugs Market
Size to Worth Around USD 65.51 Bn by 2034
